MBCProject_0096_T1_RNA
— · C
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- C
- subtype
- C
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- G2M_CHECKPOINT+0.320
- E2F_TARGETS+0.290
- PROTEIN_SECRETION+0.280
- MYC_TARGETS_V1+0.230
- SPERMATOGENESIS+0.230
- APICAL_SURFACE+0.190
- UNFOLDED_PROTEIN_RESPONSE+0.140
- ANDROGEN_RESPONSE+0.120
- ESTROGEN_RESPONSE_EARLY+0.120
- PANCREAS_BETA_CELLS+0.120
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.340
- UV_RESPONSE_UP-0.320
- HYPOXIA-0.310
- INFLAMMATORY_RESPONSE-0.280
- TNFA_SIGNALING_VIA_NFKB-0.280
- APICAL_JUNCTION-0.270
- MYOGENESIS-0.270
- TGF_BETA_SIGNALING-0.260
- COAGULATION-0.240
- MYC_TARGETS_V2-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 48507_S107 | — | cohortMD1 | 0.785 |
| 2 | TCGA-62-A46O-01A-11R-A24H-07 | — | cohortA4 | 0.783 |
| 3 | R160 | — | — | 0.776 |
| 4 | R411 | — | — | 0.762 |
| 5 | TCGA-OR-A5K4-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.762 |
| 6 | R158 | — | — | 0.760 |
| 7 | MDT-AP-3090 | Med | Medulloblastoma | 0.757 |
| 8 | MDT-AP-0314 | Med | Medulloblastoma | 0.756 |
| 9 | SRR3147748 | — | — | 0.754 |
| 10 | R320 | — | — | 0.754 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| G2M_CHECKPOINT | 0.320 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.290 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.280 | Remibrutinib | — uncovered |
| MYC_TARGETS_V1 | 0.230 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.230 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.190 | Temsirolimus | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.140 | Idelalisib | — uncovered |
| ANDROGEN_RESPONSE | 0.120 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.120 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.120 | Cobimetinib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.080 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.070 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.070 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.070 | Inavolisib | — uncovered |